Rinits alérgica

1 Cingi C, Gevaert P, Mösges R, Rondon C, Hox V, Rudenko M, et al. Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report. Clin Transl Allergy. 2017; 7(1): 17.

2 Mortz CG, Lauritsen JM, Bindslev-Jensen C, Andersen KE. Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis. Br J Dermatol. 2001; 144(3): 523–32.

3 Hong S, Son DK, Lim WR, Kim SH, Kim H, Yum HY, et al. The prevalence of atopic dermatitis,

asthma, and allergic rhinitis and the comorbidity of allergic diseases in children. Environ Health Toxicol. 2012; 27: e2012006.

4 Pinart M, Benet M, Annesi-Maesano I, von Berg A, Berdel D, Carlsen KC, et al. Comorbidity of eczema, rhinitis, and asthma in IgE sensitised and non-IgE-sensitised children in MeDALL: a population-based cohort study. Lancet Respir Med. 2014; 2(2): 131–40.

5 Hovland V, Riiser A, Mowinckel P, Carlsen KH, Carlsen KC. Asthma with allergic comorbidities

in adolescence is associated with bronchial responsiveness and airways inflammation. Pediatr Allergy Immunol. 2014; 25(4): 351–9.

6 Bousquet J, Anto JM, Wickman M, Keil T, Valenta R, Haahtela T, et al. Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The MeDALL hypothesis. Allergy. 2015; 70(9): 1062–78.

7 Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140(4): 950–8.

8 Bousquet J, Schünemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, et al. Next generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020; 145(1): 70–80.

9 Prenner BM. A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US. J Asthma Allergy. 2016; 9: 135–43.

10 Klimek L, Poletti SC, Sperl A, Spielhaupter M, Bardenhewer C, Mullol J, et al. Olfaction in patients with allergic rhinitis: an indicator of successful MP-AzeFlu therapy. Int Forum Allergy Rhinol. 2017; 7(3): 287–92.